Celyad Oncology S.A.
CYAD
Helyezés a részvények között
#31770
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Részvényárfolyam
$0.24434797
Piaci kapitalizáció
$11.55M
Változás (1 nap)
-9.25%
Változás (1 év)
-48.01%
Ország
BE
Kereskedés Celyad Oncology S.A. (CYAD)
Kategória
Healthcare
Piaci kapitalizációja Celyad Oncology S.A.(CYAD)
Piaci kapitalizáció: $11.55M
October 2026-ban a Celyad Oncology S.A. piaci kapitalizációja $11.55M. Ez alapján a Celyad Oncology S.A. a világ 31770th legértékesebb vállalata a piaci kapitalizáció szerint. A piaci kapitalizáció egy tőzsdén jegyzett vállalat összes részvényének piaci értéke, amelyet gyakran használnak a vállalat értékének mérésére.
Celyad Oncology S.A. piaci kapitalizációjának története 2015 és 2026 között
CYAD összehasonlítva az 5 legnépszerűbb stocks
